6-K 1 f6k_110723.htm FORM 6-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

________________

 

FORM 6-K

________________

 

REPORT OF FOREIGN PRIVATE ISSUER

 

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

 

November 7, 2023

________________

 

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

 

 

Novo Allé 

DK- 2880, Bagsvaerd 

Denmark

(Address of principal executive offices)

________________

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

 

Form 20-F [X]           Form 40-F [  ]

  

 
 

 

 

 

 

 

 

Trading in Novo Nordisk shares by board members, executives and associated persons

 

Bagsværd, Denmark, 7 November 2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.

 

The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.

 

Please find below a statement of such trading in shares issued by Novo Nordisk.

 

1 Details of the person discharging managerial responsibilities/person closely associated
a) Name of the Board member/Executive/Associated Person Henrik Wulff
2 Reason for the notification
a) Position/status Executive Vice President, head of Product Supply, Quality & IT
b) Initial notification/Amendment Initial notification
3 Details of the issuer
a) Name Novo Nordisk A/S
b) LEI 549300DAQ1CVT6CXN342
4 Details of the transaction(s)

 

 

 

 

 

 

 

a) Description of the financial instrument, type of instrument, Shares
  Identification code Novo Nordisk B DK0062498333
b) Nature of the transaction Sale of shares
c)





Price(s) and volume(s)





       
  Price(s) Volume(s)  
  DKK 686.03 20,000 shares  
       
       
d)

Aggregated information

  • Aggregated volume
  • Price


20,000 shares
DKK 13,720,600
e) Date of the transaction 2023-11-06
f) Place of the transaction Nasdaq Copenhagen

 

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 61,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

 

Contacts for further information

 

Media:  

Ambre James-Brown

+45 3079 9289

abmo@novonordisk.com

Elizabeth DeLuca (US)

+1 609 580 9868

edel@novonordisk.com

   
Investors:  

Daniel Muusmann Bohsen

+45 3075 2175

dabo@novonordisk.com

Jacob Martin Wiborg Rode

+45 3075 5956

jrde@novonordisk.com

 

 

 

 

 

 

 

  

 

 

 

 

David Heiberg Landsted

+45 3077 6915

dhel@novonordisk.com

Mark Joseph Root (US)

+1 848 213 3219

mjhr@novonordisk.com

   

Sina Meyer

+45 3079 6656

azey@novonordisk.com

Frederik Taylor Pitter

+45 3075 8259

fptr@novonordisk.com

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Novo Nordisk A/S

Investor Relations

Novo Alle 1

2880 Bagsværd

Denmark

Telephone:

+45 4444 8888

www.novonordisk.com
CVR no: 24 25 67 90

    Company announcement No 74 / 2023

 
 

SIGNATURES

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

 

Date: November 7, 2023

 

NOVO NORDISK A/S

 

Lars Fruergaard Jørgensen

Chief Executive Officer